Cancer Res Treat.  2002 Feb;34(1):52-57.

Expression of Cell Surface Receptors on Human Glioblastoma Xenograft Model in NOD/SCID Mouse

Affiliations
  • 1Department of Diagnostic Radiology, Kosin University College of Medicine, Busan, Korea.
  • 2Department of Neurosurgery, Dong-A University College of Medicine, Busan, Korea.
  • 3Department of Microbiology, Dong-A University College of Medicine, Busan, Korea.
  • 4Department of Diagnostic Radiology, Dong-A University College of Medicine, Busan, Korea.
  • 5Department of Pathology, Dong-A University College of Medicine, Busan, Korea. gyhuh@daunet.donga.ac.kr

Abstract

PURPOSE: To obtain basic data for development of a glioblastoma-specific immunotoxin, the expression of variable cell surface receptors on a human glioblastoma xenograft model was evaluated, using NOD/SCID mice.
MATERIALS AND METHODS
We developed a xenograft model in NOD/SCID mice implanted with a human glioblastoma cell line (U-87MG). Immunohistochemical studies were performed on implanted tumor nodules (n=8) using antibodies against CD71, EGFR, IGF-IRalpha, CXCR4 and IL-4Ralpha.
RESULTS
Expression of IL-4Ralpha, in implanted tumornodules, was the highest of the cell surface receptors evaluated in this study. However, the endothelial cells in, and around, the tumor nodules also revealed immunopositivity against IL-4Ralpha. The immunoreactivity of IL-4Ralpha, and other surface receptors such as CD71, IGF-IRalpha and EGFR, was prominent in tumor nodules associated with tumor necrosis.
CONCLUSION
IL-4Ralpha would be a possible target for the development of glioblastoma-specific immunotoxin, although there are limitations due to its endothelial expression.

Keyword

Glioblastoma; Interleukin-4 receptor; SCID mouse

MeSH Terms

Animals
Antibodies
Cell Line
Endothelial Cells
Glioblastoma*
Heterografts*
Humans*
Immunotoxins
Mice*
Mice, SCID
Necrosis
Receptors, Cell Surface*
Antibodies
Immunotoxins
Receptors, Cell Surface
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr